Bristol Myers Squibb has been a strong performer in the six months, rising over 23% in that time. Investors desiring to ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

Bristol-Myers Squibb offers 17.25% upside with strong growth prospects, cost-saving initiatives & an undervalued stock. Learn ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 11,821 calls trading, 2x expected, and implied vol increasing almost 2 points to 27.82%. May-25 67.5 calls and Mar-25 60 calls are the ...

William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...

We recently published a list of Friday’s 10 Worst Performing Stocks. In this article, we are going to take a look at where ...

Bristol Myers Squibb Co. closed 5.27% below its 52-week high of $63.33, which the company reached on March 11th.

Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

This was the stock's second consecutive day of losses.